GlassScriptPhysician profile
Carley Buddenbaum
NPI 1982174074
$16,028.94
in general payments reported to CMS, 2019-2025
29 companies · $5,261 in 2025
The $5,261 reported for 2025 was more than what 98% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $801 · 2022: $1,440 · 2023: $3,410 · 2024: $5,117 · 2025: $5,261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,287.81 |
| Education | $499.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,624.98 | 2022-2025 | |
| Janssen Biotech, INC. | $1,880.95 | 2022-2025 | Tremfya, Remicade, Simponi Aria |
| Genzyme Corporation | $1,658.77 | 2021-2025 | |
| Pfizer INC. | $1,331.55 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $924.77 | 2023-2025 | |
| Ucb, INC. | $809.53 | 2021-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $799.15 | 2022-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $796.07 | 2021-2025 | Winlevi, Absorica Ld, Ilumya |
| Regeneron Healthcare Solutions, INC. | $770.63 | 2023-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $742.61 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Amgen INC. | $659.06 | 2023-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $529.45 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $419.28 | 2024-2025 | Nemluvio, Aklief |
| Leo Pharma INC. | $414.01 | 2023-2025 | Adbry |
| Dermavant Sciences, INC. | $409.31 | 2023-2024 | Vtama |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $260.58 | 2023-2025 | Zoryve |
| Botanix Sb INC | $181.46 | 2025 | Sofdra |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $153.24 | 2023-2025 | Siliq, Arazlo, Cabtreo |
| Sanofi-Aventis U.S. LLC | $151.99 | 2021-2022 | |
| Kyowa Kirin, INC. | $138.47 | 2024-2025 | Poteligeo |
| Mayne Pharma Commercial LLC | $86.26 | 2023-2025 | |
| Kerecis Limited | $62.43 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Organon LLC | $60.09 | 2025 | Vtama |
| Kci USA, INC. | $52.42 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.25 | 2025 | Spevigo |
| Cipher Pharmaceuticals US LLC | $23.45 | 2025 | Natroba, Spinosad |
| Medimetriks Pharmaceuticals, INC. | $23.11 | 2023 | Clindacin Etz |
| Mimedx Group, INC. | $22.04 | 2024 | |
| Hartmann USA, INC. | $18.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carley Buddenbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.